

AHCC Trials Group

The Buzz

Newsletter October 2017



AHCC06 Results Presented!

Prof Pierce Chow (Protocol Chair, AHCC06) presented the results of AHCC06 at Annual Meeting in Chicago ASCO on 4 June 2017.

Contents

Page 2

Happenings

- AHCC06 – Results first presented at ASCO on 4 June 2017 in Chicago
- AHCC Trials Group – 1st SLCC Symposium

Page 5

Highlights

- AHCC07 – PLANET Study
- AHCC08 – HCC Registry in Asia

Page 7

AHCC Trials Group Secretariat

AHCC Trials Group Leadership

Group Chair:

Prof Soo Khee Chee

Protocol Chair, AHCC06, AHCC07 and AHCC08:

Prof Pierce Chow

Trial Coordinator:

Dear AHCC Trials Group members,

Warm greetings from the AHCC Trials Group.

We are delighted to welcome our new members from China, Korea, Japan and Thailand. With the start of 2 new studies, the AHCC Trials Group has grown to more than 50 members from 15 countries.

2017 has so far been an exciting year. The AHCC06 SIRveNIB clinical trial results were first presented at ASCO 2017 in Chicago by the Protocol Chair, Prof Pierce Chow. The results were next presented at APPLE 2017 in Singapore and ILCA 2017 in Seoul.

Our 2 large prospective studies, AHCC07 and AHCC08 that would place the AHCC Trials Group in the forefront of liver cancer research, have made much progress too.

The Trials Group held its 1st Singapore Liver Cancer Consortium Symposium on 13 July 2017 and the event was attended by more than 20 overseas AHCC Trials Group investigators.

We hope for more exciting collaborations, possibilities and opportunities. Thank you for your support for the AHCC Trials Group.

AHCC06 (SIRveNIB)

Phase III Multi-Centre Open-Label Randomized Control Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma

Results first presented at ASCO on 5 June 2017 in Chicago, subsequent presentation at APPLE on 14 July 2017 in Singapore and ILCA on 16 September 2017 in Seoul

The AHCC06 trial has reached an important milestone when the results were presented on 4 June 2017 at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA. ASCO is a major liver conference attended by many worldwide. The results were later presented at the 8th Asia-Pacific Primary Liver Expert (APPLE) Meeting in Singapore and International Liver Cancer Association (ILCA) 11th Annual Conference in Seoul.

News on results of the AHCC06 were published in the media. Copies of the media releases can be found at the SCRI website through this link: <http://www.scri.edu.sg/crn/asia-pacific-hepatocellular-carcinoma-ahcc-trials-group/newsroom/>

The manuscript has been submitted and is currently under review. The study is currently has on survival follow-up.

Thanks to the dedication and hard work to all the study team members inclusive of all the overseas study teams, this achievement will be impossible with their contributions.

Phase III multi-centre open-label randomized controlled trial of selective internal radiation therapy (SIRT) versus sorafenib in locally advanced hepatocellular carcinoma: The SIRveNIB study.



ASCO ANNUAL MEETING 17 #ASCO17

Piasek K.H. Chow
National Cancer Centre Singapore, Singapore
DukeNUS Medical School, Singapore

Mihir Gandhi
Singapore Clinical Research Institute, Singapore
DukeNUS Medical School, Singapore

On behalf of
The Asia-Pacific Hepatocellular Carcinoma Trials Group
(http://www.scri.edu.sg/crn/asia-pacific-hepatocellular-carcinoma-ahcc-trials-group/about-ahcc/)
(ClinicalTrials.gov: NCT01103333)

AsanaPacBio
Hepatocellular Carcinoma
Trials Group

AsanaPacBio
Hepatocellular Carcinoma
Trials Group

DukeNUS
Singapore

RIS



AHCC06 study team members and collaborators at the ASCO Annual Meeting in Chicago.

Participating Sites

Brunei

- The Brunei Cancer Centre

Indonesia

- University of Indonesia
- Sanglah General Hospital

Korea

- Asan Medical Center
- Korea Anam University Hospital
- Seoul National University Hospital
- Seoul St. Mary's Hospital
- Severance Hospital, Yonsei

Malaysia

- Penang Adventist Hospital
- Sarawak General Hospital
- University Malaya Medical Centre

Mongolia

- National Cancer Center

Myanmar

- Yangon GI & Liver Centre

New Zealand

- Auckland City Hospital

Philippines

- Makati Medical Center
- St. Luke's Medical Center
- The Medical City
- Davao Doctors Hospital

Singapore

- Khoo Teck Puat Hospital
- National Cancer Centre
- National University Hospital
- Singapore General Hospital

Taiwan

- National Taiwan University Hospital
- Chang Gung Memorial Hospital, LK
- Taipei Veterans General Hospital
- China Medical University Hospital

Thailand

- Chulabhorn Hospital

AHCC Trials Group 1st SLCC Symposium

The 1st Singapore Liver Cancer Consortium (SLCC) Symposium, under the leadership and sponsorship of the AHCC Trials Group, took place on 13 July 2017 at the National Dental Centre, Singapore. The Symposium is open to the public and brought together over 120 researchers, clinicians, scientists and partners from the industry from some 12 countries.

Since the AHCC Trials Group was established 20 years ago, it has convened 3 Scientific Forums and 9 General Meetings. These meetings are crucial in the development of liver cancer research and the continuum of these meetings represents a remarkable achievement of the Trials Group. The Scientific Forum will be renamed the SLCC Symposium to cover a wide spectrum of liver cancer research and treatment methods.

In this Symposium, the speakers included Dr Tam Zhi Yang, Senior Research Scientist from Singapore Phenome Centre, Dr Choo Su Pin, Senior Consultant from National Cancer Centre, Ms Lisa Marie Saldanha, Head of Academic Research Group from QuintilesIMS and Dr Tam Wai Leong, Senior Research Scientist from Genome Institute of Singapore.

The organizing committee and the members celebrated the 20th anniversary of the AHCC Trials Group during the Symposium. In the afternoon, respective investigators attended the AHCC Trials Group 10th General Meeting and the AHCC07 2nd General Meeting. The AHCC08 1st Steering Committee Meeting was held during the same week. All the investigators were invited to the AHCC Trials Group dinner in the evening. It was a good networking session for the members, especially the new members from the AHCC07 and AHCC08 studies.

The AHCC Trials Group looks forward to the next SLCC Symposium and General Meeting in mid of 2018. Meanwhile, the Trials Group will work towards more collaborations with research institutions and industrial partners.



Picture of Investigators from the AHCC Trials Group taken during the 10th AHCC Trials Group General Meeting on 13 July 2017.

AHCC Trials Group Dinner

Prima Tower Revolving Restaurant

13 July 2017



AHCC07 (PLANET study)

A Multi-national Cohort Study on the Clinical Trajectory of Resected Hepatocellular Carcinoma (HCC)

Precision Medicine in Liver Cancer across an Asia-Pacific Network

Lead PI: Prof Pierce Chow, NCCS, SGH and Duke-NUS

Theme PIs: Dr Zhai Weiwei, GIS

Prof Salvatore Albani, STIIC

Prof Pierce Chow, NCCS



Participating Sites

Malaysia

- University Malaya Medical Centre

Philippines

- The Medical City

Singapore

- National Cancer Centre

- National University Hospital

- Singapore General Hospital

Thailand

- National Cancer Institute Thailand

Members of the AHCC07 study during the Investigators Meeting held in Singapore on 27 August 2016.

In 2017, the AHCC07 PLANet study has made good progress with its scientific findings published in the scientific journal Nature Communications, under the title, “The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma”. Press release of the publication is available on <https://www.a-star.edu.sg/News-and-Events/News/Press-releases/ID/5409/Doctors-a-step-closer-to-giving-liver-cancer-patients-a-more-precise-treatment.aspx>

The study also held its 2nd Investigator Meeting on 13 July 2017. All 6 sites participated in meeting and challenges of the study were presented and discussed.

The first patient was recruited in October 2016 in Singapore. National Cancer Institute Thailand (NCI) and University Malaya Medical Centre (UMMC) recruited their patient on 13 June 2017 and 14 September 2017 respectively. The overall recruitment is about 20%. The Medical City (TMC) is expected to start recruitment in by the end of 2017.

The AHCC07 study team members are in talks with industrial partners regarding possible treatment post-recurrence and big data integration.

The study is in preparation for its 2nd Scientific Advisory Board (SAB) on-site review which will be in the mid of next year.

AHCC08

Hepatocellular Carcinoma (HCC) Registry in Asia

Protocol Chair: Prof Pierce Chow, NCCS, SGH and Duke-NUS



Members of the AHCC08 study during the Investigators Meeting held in Singapore on 27 August 2016.

Participating Sites

China

- Beijing Cancer Hospital (BCH)
- Guangxi Medical University Cancer Center (GXM)
- Nanjing Bayi Hospital (NJB)
- Second Affiliated Hospital Zhejiang University School of Medicine (SAH)
- Zhongshan Hospital, Fudan University (ZSH)

Japan

- University of Tokyo (UTJ)

Singapore


- National Cancer Centre (NCS)
- National University Hospital (NUH)

The AHCC08 study, HCC Registry in Asia held recruited its first patient in April 2017. Currently, there are 8 active sites and more will join the study by the end of 2017. This longitudinal cohort study aims to collect real world data from 2,500 patients from 9 countries in Asia Pacific to provide a complete longitudinal picture of the HCC patient journey. This large database could possibly elucidate patterns in liver cancer that could help with developing government policies. As the data available on liver cancer in each country differs, this registry could also help fill in the gaps in specific countries.

The steering committee met for the first time on 16 July 2017. The committee will provide scientific oversight for the registry. It will also be responsible for the direct scientific analyses which will lead to scientific publications. The study team is also working a research plan to leverage on the registry.



A group picture of the Steering Committee Members with the study team members after the meeting on 16 July 2017.



From left, Dr Chien-Hung Chen, Prof Joon Hyeok Lee, Prof Simone Strasser, Prof Pierce Chow, Mr Mihir Gandhi, Dr Senthil Sockalingam, Mr Chris King and Dr Gao Song.



The Investigators took a tour at the SGH museum during the lunch break after the 1st SLCC Symposium on

Since the conception of the AHCC Trials Group in 1997, the AHCC Trials Group Secretariat led by Prof Pierce Chow has been involved in the general administration and management of the AHCC Trials Group network. The Secretariat has been maintaining the network registry, website, social media sites and the publishing of the periodic newsletters for the network to keep the group abreast of any developments and happenings across the network. The Secretariat works closely with academic clinical trials organizations, pharmaceutical and biotech industry partners to organize the General Meetings, Scientific Forums as well as ad-hoc meetings of the trials group.

The AHCC Trials Group will like to thank all the members and collaborators for their support.

Contact Details

For further queries, please contact the AHCC Trials Group at

Network Secretariat:

Ms Lynette Lai

Email: lynette.lai.s.h@sqh.com.sg / ahcctrialsgroup@nccs.com.sg

DID: (65) 6326 2151

Dr Chew Sin Chi

Email: chew.sin.chi@nccs.com.sg

DID: (65) 6576 6450

Mailing Address: 31 Biopolis Way Nanos #02-01 Singapore 138669

Read more about all trials
under AHCC Trials Group at
<http://www.scri.edu.sg>.